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CMV is the most common congenital infection.1 Congenital CMV (cCMV) is diagnosed if the 
virus is isolated in the first three weeks of life. It is challenging to differentiate between 
congenital and postnatal infection (pCMV) if the virus is detected after this time point. 
Retrospective diagnosis of cCMV requires identification of the virus on the Dried Blood Spot, a 
method which has been shown to be insensitive.2 Additionally, there are are no internationally 
accepted definitions for symptomatic pCMV.  
More than 90% of seropositive mothers shed CMV into their breast milk; breast milk is therefore 
an important mode of transmission of CMV to newborn infants.3 
The great majority of term newborns acquiring CMV infection postnatally remain asymptomatic 
and have no long term consequences. This contrasts with cCMV infection and may be explained 
by the intensity and route of exposure: CMV viral loads in urine are lower in infants with pCMV 
compared to infants with cCMV.4 Nonetheless very premature (gestational age <32 weeks) or 
very low birth weight (VLBW, <1500 grams) infants are susceptible to developing symptomatic 
illness following acquisition of CMV in the postnatal period. A recent prospective multicenter 
study in Atlanta of 539 VLBW infants revealed that the incidence of CMV acquisition at 12 
weeks of age was 6.9% (95% CI, 4.2% - 9.2%).5 Of these, 17% developed symptomatic disease 
or died.  
Various clinical signs and syndromes have been described in infants with pCMV infection, 
including severe sepsis-like syndrome (SLS), pneumonia, hepatitis, renal impairment and 
thrombocytopaenia.6 Table 1 summarizes the clinical manifestations and investigations that 
should be considered in managing infants with pCMV. 







A key issue is the potential for pCMV infection to cause adverse long-term outcomes. To date, 
studies investigating clinical sequelae have been small, single center and open to confounding 
due to study design. Although no impact on hearing has been reported in any study, a small case 
controlled study showed that children at school age who had pCMV as a preterm (through breast 
milk acquisition) had poorer cognitive function and motor skills, although still within the normal 
range, compared to controls.7 Another prospectively controlled study of 42 VLBW infants 
showed that infants with pCMV had significantly lower cognitive results using the Kaufman 
Assessment Battery for Children (K-ABC).8 Other studies of postnatally infected preterm infants 
have shown that white matter changes including lenticulostriate vasculopathy are more common 
than in non-infected infants, although the significance of this for long-term outcomes remains 
unknown.4, 9 
These potential long-term effects, in addition to sometimes very severe acute illness, raise the 
question of whether antiviral therapy may have a role in pCMV infection.  
There are no controlled studies which have evaluated the efficacy or safety of antiviral or 
immunoglobulin based treatment for symptomatic infants with pCMV, nor are there robust data 
to show improved short or long term outcomes. In particular, there are very limited safety and 
pharmacokinetic data on antiviral treatment in preterm infants; the group most likely to have 
severe disease.  
As a consequence, the evidence on which to base treatment guidelines for the management of 
pCMV is sparse.  Many clinicians therefore reserve treatment for babies with significant 
disease.10 
There are therefore significant uncertainties regarding the management of infants with pCMV 
disease, in part due to our limited understanding of the natural history of disease. 







This review will therefore focus on possible strategies to minimize CMV transmission and 
disease in this vulnerable group by focusing on prevention and pre-emptive therapy.   
Prevention.  
It is possible to prevent transmission of CMV by treating breast milk through heat pasteurization 
or freeze-thawing. However, freeze thawing does not fully prevent transmission and heat 
pasteurization can negate some of the benefits of breast milk by decreasing its fat and lactose 
constituents.11, 12 The most recent conclusion from the American Academy of Pediatrics is that 
the benefits of giving fresh breast milk in CMV positive mothers outweigh the risks.13 
To our knowledge, only one placebo controlled trial of CMV immunoglobulin has been 
published.14 This study was conducted before CMV negative blood transfusions were used as 
part of routine clinical care and showed that immunoglobulin reduced the likelihood of 
transmission compared to placebo (12.5% VS 3.2%). The results of a prospective cohort study 
conducted in Solid Organ Transplant (SOT) recipients to evaluate the neutralizing capacity of 
monoclonal antibodies in preventing viral transmission are awaited (NCT01753167). Promising 
results in this population could lead to similar trials to reduce transmission in maternal-fetal 
transfer.  
Pre-emptive screening in SOT recipients  
The adoption of CMV specific antiviral therapy screening strategies has reduced the incidence of 
CMV disease amongst SOT recipients.15 Pre-emptive screening involves administration of 
antiviral therapy in response to laboratory triggers, such as increasing viral load. Pre-emptive 
treatment is used as an alternative to antiviral prophylaxis for SOT recipients at high risk of 
CMV disease who are prospectively screened for CMV viremia. This strategy is based upon 







knowledge of the natural history of CMV viremia in adult SOT patients and recognition that a 
“threshold” can exist below which virus is tolerated without associated disease.  
A meta-analysis by Strippoli concluded that compared with placebo or standard care, pre-
emptive treatment significantly reduced the risk of CMV disease and comparative trials of pre-
emptive therapy versus prophylaxis showed no significant differences in the risks of CMV 
disease.16 These studies are limited to adult SOT populations and there are no data which define 
viral threshold limits in pCMV.   
Identifying pre-symptomatic pCMV infection  
A successful pre-emptive screening strategy would require a readily available, rapid, sensitive 
and easy to use surveillance test for CMV detection. Real-time PCR on plasma or whole blood 
has been shown to be sensitive with turnaround times of 24 hours.17  Point-of-care PCR assays 
are now also commercially available but have not yet entered clinical trials in neonates.  Saliva 
swabs require no skills to obtain and are therefore a painless and highly accurate method of 
detecting the virus.17 
Pre-emptive screening in preterms 
Serial saliva samples could be obtained in preterm infants to test for CMV DNA using PCR to 
enable early identification of infection. Developing a strategy whereby saliva samples are taken 
at regular time intervals by health care staff on the neonatal unit in infants less than 32 weeks and 
sent to a regional laboratory for same day testing is conceivable. Batch testing of samples would 
further reduce costs.  When CMV is detected treatment could be started before symptoms 
develop. 







Such a strategy could be coupled with prospective data collection in order to monitor outcomes 
and to model and define the relevance of different virologic parameters, using similar 
methodologies to those utilized in adult SOT populations.18 
There are many questions which need to be addressed before considering a strategy of pre-
emptive screening for pCMV. The clinical burden of pCMV disease is largely unknown, in part 
due to the limited long term outcome data available.  No studies have yet shown that antiviral 
treatment in infants with asymptomatic CMV infection is beneficial and the side effects of 
therapy in this preterm population still need to be clearly defined.  
Linking outcomes in this well-defined patient group to existing neonatal datasets would, 
however, enable detailed data collection and allow comparison with non-CMV infected groups 
to start to address some of these questions.     
Conclusions  
Postnatal acquisition of CMV can cause severe acute disease in preterm infants but the longer-
term consequences remain uncertain. The options available for prevention, such as pasteurization 
of breast milk, are limited and their evidence base is inadequate. An approach which has been 
successfully adopted in a different setting (adult organ transplantation) is pre-emptive screening 
of susceptible patients to detect pre-symptomatic infection and then treatment of those with a 
high risk of severe disease.   
Recruiting subjects to a randomized controlled trial to evaluate the efficacy and safety of oral 
valganciclovir in postnatally acquired cases would take several years and need multiple 
recruiting sites due to the inherent difficulties of conducting antiviral treatment trials for rare 
diseases in the neonatal population. Disease registries, however, can efficiently collect high 
quality safety and pharmacokinetic data in infants treated with antivirals which in turn can be 







used to guide dosing and duration of treatment recommendations. Improving our understanding 
of the epidemiology of pCMV disease is also essential to inform evidence based management.  
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Table 1: Summary of risk factors, clinical features and investigations that should be considered 
when managing an infant with pCMV. This table was derived from data from key publications 
3,13, 19 
 
Risk factors  Gestational age <32 weeks, birth weight 
<1500gm, seropositive mothers breast 
feeding, early detection of virolactia, high 
virus burden in breast milk and long 
duration of virus detection in breast milk  
Diagnosis  CMV positive sample (saliva or urine 
sample to test for CMV DNA PCR) 
detected >21 days of life and CMV 
negative sample collected <21 days of 
life  
Clinical features CMV sepsis-like syndrome (triad of 
apneas, bradycardias, grey / pallor), acute 
hepatitis, hepatosplenomegaly and CMV 
pneumonia, CMV enterocolitis, jaundice, 
cholestasis, petechiae and 
lymphadenopathy  
Laboratory investigations  Full Blood Count (thrombocytopenia and 
neutropaenia) and Liver Function Test 
(elevated liver enzymes) 
Neuroimaging  Serial cranial ultrasound (CrUSS) from 
diagnosis to hospital discharge to assess 
for cerebral abnormalities including 
lenticulostriate vasculopathy. 
Consideration of MRI if abnormalities 
seen on CrUSS  
Treatment  Consider treatment in severely 
symptomatic infants using 
ganciclovir/valganciclovir. Any decision 
to commence treatment should be made 
after discussion with local pediatric 
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